What iSiP does
iSiP builds an AI drug-discovery platform it calls "AI Drug Discovery 3.0," which combines machine-learning-based molecular design with physical simulation and high-performance computing. Rather than applying one general model, the company says it uses AI models tailored to each of the four stages of small-molecule drug discovery, from hit discovery through lead optimization, to design first-in-class drug candidates. Following its Series A round, DNX Ventures said iSiP would use the new AI drug-discovery engine to begin searching for new compounds and synthesizing and optimizing them into candidate medicines, while also expanding its team. iSiP was founded in 2022 and is based in Bunkyo, Tokyo.
iSiP is a healthcare tool on Falcoscan. AI drug-discovery engine that designs new small molecules stage by stage. Falcoscan rates iSiP with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. iSiP is founded in 2022, currently at Series_a stage. Pricing: Paid.